CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for PRISM BioLab Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

PRISM BioLab Co Ltd
Shonan I Park, 2-26-1, Muraoka-Higashi
Phone: +81 466538383p:+81 466538383 FUJISAWA-SHI, KNG  251-8555  Japan Ticker: 206A206A
Business Summary
PRISM BioLab Co Ltd is a Japan-based company mainly engaged in the drug discovery business. The Company operates through Japan drug discovery business segment. The Company builds a new drug discovery platform and develops new drugs. The Company conducts research and development of pharmaceuticals using their owned drug discovery platform technology PepMetics technology. There are two business models. The in-house development business is engaged in the select of drug discovery targets and creates programs in-house. The joint development business creates programs using their owned technology to target drug discovery targets for pharmaceutical companies.
(Source: N-30D)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20249/30/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Representative Director DaiTakehara
Chief Financial Officer, Director in Administration Unit, Director MichihiroMaeda
Chief Technology Officer TetsuyaToma
Director of Research and Development, Director Hyi-manPark

General Information
Number of Employees: 22 (As of 4/30/2024)
Outstanding Shares: 35,954,800 (As of 7/31/2024)
Stock Exchange: TYO
Fax Number: +81 466549393


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024